Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450218 | 0.87 | LRRK2 (0.56) | MAPK14MAPK11LRRK2 | |
| SCHEMBL24963384 | 0.84 | IKBKB (0.57) | MAPK14MAPK11LRRK2 | |
| SCHEMBL5258393 | 0.84 | IKBKB (0.57) | MAPK14MAPK11LRRK2 | |
| SCHEMBL5446476 | 0.84 | IKBKB (0.57) | LRRK2 | |
| SCHEMBL14519374 | 0.83 | LRRK2 (0.60) | LRRK2 | |
| SCHEMBL14519418 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL5258469 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL5450217 | 0.82 | LRRK2 (0.56) | MAPK14MAPK11LRRK2MAPK13MAPK12 | |
| SCHEMBL5443403 | 0.81 | MAPT (0.56) | LRRK2 | |
| SCHEMBL5447914 | 0.81 | LRRK2 (0.52) | MAPK14MAPK11LRRK2MAPK13GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| EP-2784070-A1 | 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES | Bayer CropScience AG (DE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2784072-A1 | 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES | Bayer CropScience AG (DE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2784073-A1 | 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES | Bayer CropScience AG (DE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2784071-A1 | 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES | Bayer CropScience AG (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-20130281455-A1 | Phenylpyri(mi)dinylazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-2486031-A2 | Phenylpyri(mi)dinylpyrazoles and their use as fungicides | Bayer CropScience AG (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20110183978-A1 | Phenylpyri(mi)dinylazoles | BAYER CROPSCIENCE AG (DE) | 2011-07-28 | — | — | US | disclosed |
| WO-2011042389-A2 | PHENYLPYRI(MI)DINYLAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-04-14 | — | — | WO | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| CN-1273603-A | Attenuated respiratory syncytial virus | AMERICAN CYANAMID CO (US) | 2000-11-15 | — | — | CN | disclosed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281455-A1 | Phenylpyri(mi)dinylazoles | PIR, PIN4, PNN | MAPK14 1078/4885MAPK11 1608/4885LRRK2 4282/4885 |
| US-20110183978-A1 | Phenylpyri(mi)dinylazoles | PIR, PIN4, PNN | MAPK14 1078/4885MAPK11 1608/4885LRRK2 4282/4885 |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | MAPK14 12/4885MAPK11 96/4885LRRK2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.